Aarti Drugs reports strong Q1 FY27 results: Revenue up 19% to ₹703.6 Cr, EBITDA up 30% to ₹96.9 Cr.

Adjusted PAT soared 29% (excluding prior year's tax refund). Specialty Chemicals grew 150%. Expansion includes Sayakha ramp-up and OSD capacity doubling at Baddi.